Oncology

GENERIC:
CYCLOPHOSPHAMIDE

CLASSIFICATION:
Alkylating agent

MECHANISM OF ACTION:
Active metabolites interfere with growth of rapidly proliferating malignant cells. Polyfunctional alkylating agent may cross-link DNA, interfering with DNA replication and transcription of RNA, disrupting nucleic acid function. Also has potent immunosuppressive activity. The drug exhibits phosphorylating properties that also enhance its cytotoxicity.

COMPOSITION
Cyclophosphamide Injection I.P.
Each vial contains;
Cyclophosphamide I.P equivalent to anhydrous Cyclophosphamide
200mg 500mg 1 g

INDICATION:

• Breast Cancer
• Small cell lung cancer
• Ovarian cancer
• Leukemia
• Multiple myeloma
• Hodgkin's disease
• Non-Hodgkin's disease.

STORAGE:
Oral,Tablets
Tight containers at 25ºC (may be exposed briefly to temperatures up to 30ºC); protect from >30ºC.
Parenteral
Powder for Injection
25ºC (may be exposed briefly to temperatures up to 30ºC);Protect from >30ºC.

STRENGTHS:

• CYCRAME INJ. 200MG
• CYCRAME INJ. 500MG
• CYCRAME INJ. 1GM

GENERIC:
DAUNARUBICIN

CLASSIFICATION:
Antitumor Antibiotic

COMPOSITION:
Each Vial Contains:
Daunorubicin Hydrochloride USP
Equivalent to Daunorubicin ……….20mg

MECHANISM OF ACTION:
Daunorubicin has antimitotic and cytotoxic activity through a number of proposed mechanisms of action: Daunorubicin forms complexes with DNA by intercalation between base pairs, and it inhibits topoisomerase II activity by stabilizing the DNA-topoisomerase II complex, preventing the religation portion of the ligation-religation reaction that topoisomerase II catalyzes.

INDICATIONS:

• Acute lymphocytic leukemia
• Acute granulocytic leukemia
• Acute myeloblastic leukemia

STORAGE:
Store unopened vials in refrigerator, 2° to 8°C (36° to 46°F). Store prepared solution for infusion at room temperature, 15° to 30°C (59° to 86°F) for up to 24 hours. Contains no preservative. Discard unused portion. Protect from light.

STRENGTHS:

• DAUNOPLUS INJ. 20MG

GENERIC:
5-FLUOROURACIL

CLASSIFICATION:
Antimetabolite

COMPOSITION:
Each ML Contains: Fluorouracil ……50mg (As Flouracil Sodium) Water fro Injection…q.s.

STRENGTHS:

• Flocil INJ 250 MG/5ml
• Flocil INJ 500 MG /10ml

MECHANISM OF ACTION:
As a pyrimidine analogue, it is transformed inside the cell into different cytotoxic metabolites which are then incorporated into DNA and RNA, finally inducing cell cycle arrest and apoptosis by inhibiting the cell's ability to synthesize DNA. It is an S-phase specific drug and only active during certain cell cycles.

INDICATION:

• Colorectal Cancer-adjuvant setting and advanced disease.
• Breast Cancer-adjuvant setting and advanced disease.
• GI malignancies, including anal, esophageal, gastric, and pancreatic Cancer.
• Head and Neck Cancer.
• Topical use in basal cell cancer of skin and actinic keratoses.
• Ovarian Cancer.

STORAGE:
Protect from light. It should be stored at temperature 10o C- 30 o C

GENERIC:
VINCRISTINE

CLASSIFICATION:
Mitotic inhibitor

MECHANISM OF ACTION:
Vincristine prevents the formation of spindle fibers during metaphase of mitosis. It binds to tubulin, the protein that makes up the spindle fiber microtubules, and prevents metaphase of mitosis.

COMPOSITION:
Each ml Contains:
Vincristine Sulphate I.P. …….1 mg
Mannitol I.p. …………100mg
Methyl paraben I.P……13% v/v
Propyl Paraben I.P…….0.02% v/v

INDICATIONS:

• Acute lymphocytic leukemia.
• Acute myelogenous leukemia
• Hodgkin's lymphoma
• Non-Hodgkin's lymphoma

STORAGE:
This product should be refrigerated between 2°- 8° C (36°- 46° F)

STRENGTHS:

• IVIN INJ. 1MG/1ML

GENERIC:
MEROPENEM

CLASSIFICATION:
BETA LACTUM ANTIBIOTIC

MECHANISM OF ACTION:
Meropenem is bactericidal except against Listeria monocytogenes where it is bacteriostatic. It inhibits bacterial wall synthesis like other beta-lactam antibiotics. In contrast to other beta-lactams, it is highly resistant to degradation by beta-lactamases or cephalosporinases. Resistance generally arises due to mutations in penicillin binding proteins, production of metallo-beta-lactamases, or resistance to diffusion across the bacterial outer membrane. Unlike imipenem, it is stable to dehydropeptidase-1 and can therefore be given without cilastatin.

COMPOSITION:
Each vial Contains:
Meropenem USP (Sterile) equivalent to Anhydrous Meropenem ….500mg
Sodium Carbonate equivalent to to Sodium …43 mg
Meropenem USP (Sterile) equivalent to Anhydrous Meropenem ….1g
Sodium Carbonate equivalent to to Sodium …86 mg

INDICATIONS:
Febrile neutropenia
Nosocomal infections
septicemia

STORAGE:
Store in dry cool place
Protect from light

STRENGTHS:
500mg, 1gm

GENERIC:
HYDROXYUREA

CLASSIFICATION:
Antimetabolite.

COMPOSITION:
Each Capsule Contains 500mg of Hydroxyurea.

MECHANISM OF ACTION:
Hydroxyurea is thought to be cell cycle-specific for the S phase of cell division. The exact mechanism of antineoplastic activity is unknown but is thought to involve interference with synthesis of DNA, with no effect on synthesis of RNA or protein.

INDICATIONS:

• Ovarian cancer
• Cervical cancer
• Chronic myelogenous leukemia
• Head and neck cancer
• Melanoma
• Sickle cell anemia

STORAGE:
Store in a cool and dark place,Protect from moisture and light.

STRENGTHS:

• NEODREA CAP 500 MG

GENERIC:
CISPLATIN

CLASSIFICATION:
Alkylating like agents, miscellaneous agent

COMPOSITION:
Platifirst Injection BP 10mg/10ml
Each ml contains:
CisplatinI.P. ……….10mg

Platifirst Injection BP 50mg/50ml
Each ml contains:
CisplatinI.P. ……….50mg

MECHANISM OF ACTION:
Cisplatin is similar to the bifunctional alkylating agents. It covalently binds to DNA and disrupts DNA function. After cisplatin enters the cells, the chloride ligands are replaced by water molecules. This reaction results in the formation of positively charged platinum complexes that react with the nucleophilic sites on DNA. These platinum complexes covalently bind to DNA bases using intra-strand and inter-strand cross-links creating cisplatin-DNA adducts thus preventing DNA, RNA and protein synthesis. This action is cell cycle phase-nonspecific. Cisplatin has immunosuppressive, radiosensitizing, & antimicrobial properties.

INDICATION:

• Ovarian cancer
• Testicular teratoma.
• Cervix cancer.
• Breast cancer.
• Head and neck cancer.

STRENGTHS:

• PATIFIRST INJ 10 MG/10ml
• PLATIFIRST INJ 50 MG/50ml

STORAGE:
Cisplatin is available as sterile, unpreserved; single-dose vials (10 mg/10 mL & 50 mg/50 mL. Unopened vials are stored at room temperature. Do not refrigerate or freeze cisplatin solutions, as a precipitate will form. Protect from light.

GENERIC:
IFOSFAMIDE

CLASSIFICATION:
Alkylating agent

MECHANISM OF ACTION:
Its mode of action consists of interference with DNA action by reaction with phosphodiester bridges thus preventing the cell division. It is considered to be cell cycle non-specific.

COMPOSITION:
Each vial contains
Soloxan 500 mg Combipack
Ifosfamide USP…..500 mg

Each vial contains
Soloxan 1g Combipack
Ifosfamide USP…..1g

Each vial contains
Soloxan 2g Combipack
Ifosfamide USP…..2g

INDICATION:

• Cervical cancer (single agent or combination)
• Sarcoma, soft tissue (1st or 2nd line)
• Pancreatic cancer (2nd line
• Breast cancer
• Non-Hodgkin's lymphoma.

STORAGE:

• Ifosfamide injection: store at 2°C to 8°C (36° to 46°F)
• Mesna injection: store at 2°C to 30°C (36° to 86°F)

STRENGTHS:

• SOLOXAN 500MG
• SOLOXAN 1GM
• SOLOXAN 2GM